Bristol-Myers Squibb logo

Bristol-Myers SquibbBMY

NYSE

Pharmaceuticals

$59.00+0.67%

AI Multi-Horizon Analysis

Short-term35% confidence
Neutral

Price anchored near $62.44 with thin intraday information; no decisive momentum.

Mid-term50% confidence
Neutral

Trading in low-to-mid $60s after insider sales; margin contraction may weigh on sentiment while strong FCF offers support.

Long-term50% confidence
Neutral

Improving equity, declining leverage and robust FCF support long-term funding needs, but margin volatility, product concentration and competition remain risks.

Overall AI View45% confidence
Neutral

Solid balance sheet, FCF acceleration and deleveraging are constructive, but offset by sharp sequential margin/net-income contraction, routine insider sales, and mixed product momentum. No clear directional edge.

Detailed AI Fundamental Analysis

## Business Snapshot

Bristol-Myers Squibb Co. (BMY) is a large-cap pharmaceutical company focused on discovery, development, and commercialization of medicines in oncology, immunology, cardiovascular disease, and other therapeutic areas. With a market capitalization of approximately $127 billion and roughly 32,500 employees, BMY trades as common stock on the NYSE. The company maintains a substantial pipeline and portfolio of established and newly launched products. Current share price stands at $62.44.

## Financial Trends

Revenue has shown modest sequential growth in the most recent two quarters: Q3 2026 revenue of $13.069 billion versus $12.973 billion in Q2 2026 (+0.7%). Earlier, Q2 revenue rose sharply from Q1 2026’s $11.489 billion (+12.9%). Full-year 2025 revenue was $48.194 billion, indicating the quarterly run-rate has stabilized near the $12–13 billion level.

Net margin trajectory has been volatile. Q3 2026 net margin contracted sharply to 16.54% from 25.57% in Q2 2026 (−9.03 percentage points). This follows an improvement from Q1 2026’s 23.30% and a full-year 2025 net margin of 14.64%. The latest quarter therefore represents a notable deceleration in profitability.

Free cash flow (FCF) demonstrates strong acceleration through the first three quarters of 2026. Q3 FCF reached $7.682 billion versus $3.845 billion in Q2 (+$3.837 billion or +100%). Q2 itself improved dramatically from Q1’s $757 million. Compared with the year-earlier period implied by the 2025 full-year figure of $12.845 billion, the quarterly FCF run-rate has strengthened materially in recent periods.

Balance-sheet strength continues to improve. Shareholders’ equity has expanded steadily from $18.473 billion at year-end 2025 to $23.404 billion at the end of Q3 2026 (+$4.931 billion or +26.7% over four periods). Debt/Equity ratio has declined from 2.32 to 1.79, reflecting deleveraging. Current ratio has risen from 1.26 to 1.59, and working capital has nearly doubled from $5.973 billion to $11.014 billion. Long-term debt has been reduced by approximately $1.0 billion since year-end 2025.

## Financial Health

At the end of Q3 2026, BMY exhibits solid financial health supported by a multi-quarter positive trend. Liquidity is comfortable with a current ratio of 1.59 and $9.574 billion in cash and equivalents. The balance sheet has strengthened markedly over the past year, with equity growing rapidly, leverage declining, and working capital expanding. Operating cash flow remains robust at $8.678 billion in the latest quarter. The primary caution is the sharp sequential drop in net margin and net income ($2.162 billion in Q3 versus $3.317 billion in Q2), suggesting either one-time items, higher operating expenses, or product-mix pressure that bears monitoring. Overall trajectory remains constructive on leverage, liquidity, and cash generation.

## Insider Activity

Recent Form 4 filings (October–November 2026) show a pattern of routine equity compensation vesting followed by share sales among multiple executives. Julia Haller sold 3,800 shares for $240,578. Adam Lenkowsky, Christopher Boerner, Karin Shanahan, and Gregory Meyers each received shares via grants (at $0 cost basis) and subsequently sold portions to cover taxes or realize gains, with sale proceeds ranging from approximately $107,715 to $237,460. No open-market purchases were reported. The volume of sales after vesting is typical for executive compensation cycles and does not indicate unusual negative sentiment; however, the absence of any disclosed insider purchases during this window is neutral to mildly cautious.

## Multi-Timeframe Technical Context

On the ultra-short (intraday/minutes) horizon, price action is centered near the $62.44 level with limited session range data provided. Short-term (hours-to-days) context shows the stock trading in the low-to-mid $60s following recent insider sales around $61.71–$63.31. Over the longer (weeks-to-months) horizon, the balance-sheet improvement and accelerating FCF provide fundamental support, yet the recent margin compression may weigh on sentiment. No specific moving-average, RSI, or volume indicator values were supplied in the current payload; therefore technical overlays cannot be precisely quantified. Price remains below the psychological $65–$70 zone that would signal broader recovery.

## Bull / Bear Cases

Short-term Bull Case: Continued strong operating cash flow and FCF acceleration could support a relief rally if Q3 margin pressure is viewed as transitory. Any positive pipeline updates or stabilization in the $62–$64 zone may encourage near-term buying.

Short-term Bear Case: The sharp sequential drop in net income and margin may trigger further selling pressure, especially if accompanied by soft guidance or disappointing product sales trends. Routine but sizable insider sales could add to near-term supply.

Long-term Bull Case: Sustained equity growth, declining leverage, and robust quarterly FCF generation position BMY to fund its dividend, pipeline investment, and potential bolt-on acquisitions. Successful commercialization of new therapies could drive revenue re-acceleration and margin recovery over the next 12–24 months.

Long-term Bear Case: Persistent margin volatility, heavy reliance on key products, and competition in oncology/immunology could pressure earnings if new launches disappoint. Elevated absolute debt levels ($41.8 billion long-term) still require ongoing management even as the debt/equity ratio improves.

## Key Levels & Triggers

  • Immediate support: $61.70–$62.00 zone (recent insider sale prices and round-number support).
  • Near-term resistance: $63.30–$65.00 (recent highs and psychological level).
  • Bull trigger: Sustained move above $65 accompanied by margin stabilization or positive clinical news.
  • Bear trigger: Decisive break below $61 on increased volume, especially if tied to further margin deterioration or negative pipeline updates.
  • Longer-term milestone: Reclaim of $70+ would require clear evidence of revenue re-acceleration and sustained FCF above $5–6 billion per quarter. Monitoring of next quarterly results for margin trajectory will be the most important fundamental trigger.

Financials

From SEC EDGAR · Period 2026-09-30 · Source form 10-Q

Income Statement · last 4 periods

 
2026-09-30
10-Q
2026-06-30
10-Q
2026-03-31
10-Q
2025-12-31
10-K
Revenue$13.07B$12.97B$11.49B$48.19B
Net Income$2.16B$3.32B$2.68B$7.05B
EPS (Diluted)$1.05$1.62$1.31$3.46
Net Margin16.54%25.57%23.30%14.64%

Balance Sheet · last 4 periods

 
2026-09-30
10-Q
2026-06-30
10-Q
2026-03-31
10-Q
2025-12-31
10-Q
Total Assets$88.77B$87.63B$86.48B$90.04B
Total Liabilities$65.37B$65.31B$66.37B$71.53B
Shareholders' Equity$23.40B$22.32B$20.07B$18.47B
Cash & Equivalents$9.57B$8.72B$9.57B$10.21B
Long-term Debt$41.85B$42.09B$42.15B$42.85B
Current Ratio1.591.531.421.26
Debt / Equity1.791.892.102.32

Cash Flow · last 4 periods

 
2026-09-30
10-Q
2026-06-30
10-Q
2026-03-31
10-Q
2025-12-31
10-K
Cash from Operations$8.68B$4.50B$1.10B$14.16B
Cash from Investing-$3.85B-$1.75B-$131.00M-$4.13B
Cash from Financing-$5.41B-$4.19B-$1.56B-$10.35B
Capital Expenditures$996.00M$652.00M$347.00M$1.31B
Free Cash Flow$7.68B$3.85B$757.00M$12.85B

Income Statement

Revenue
$37.53B
Gross Profit
$30.75B
Operating Income
$1.40B
Net Income
$8.16B
EPS (Basic)
$4.00
EPS (Diluted)
$3.98

Balance Sheet

Total Assets
$88.77B
Total Liabilities
$65.37B
Shareholders' Equity
$23.40B
Cash & Equivalents
$9.57B
Long-term Debt
$41.85B
Shares Outstanding
2.04B

Cash Flow

Cash from Operations
$8.68B
Cash from Investing
-$3.85B
Cash from Financing
-$5.41B
Capital Expenditures
$996.00M
Free Cash Flow
$7.68B

Key Ratios

Gross Margin
81.92%
Operating Margin
3.74%
Net Margin
21.73%
Current Ratio
1.59
Debt / Equity
1.79
Free Cash Flow
$7.68B

Insider Activity

5 insider filings (2026-10-10 to 2026-11-09) — sourced directly from SEC Forms 4/5

Buys
$0.00 · 5
Sells
$953.0K · 9
Net
-$953.0K
Filings Parsed
5
Trade DateInsiderActionSharesPriceValue
2026-11-05Haller Julia ASell3,800$63.31$240.6K
2026-11-03Lenkowsky AdamBuy7,522$0.00$0.00
2026-11-03Lenkowsky AdamSell3,848$61.71$237.5K
2026-11-03Lenkowsky AdamSell7,522$0.00$0.00
2026-11-01BOERNER CHRISTOPHER S.Buy2,964$0.00$0.00
2026-11-01BOERNER CHRISTOPHER S.Buy406$0.00$0.00
2026-11-01BOERNER CHRISTOPHER S.Sell1,724$62.48$107.7K
2026-11-01BOERNER CHRISTOPHER S.Sell2,964$0.00$0.00

Key Stats

$120.19BMarket cap
$62.8952-week high
$42.5252-week low
11,682,050Avg volume (30d)

32,500 employees2.04B shares outstandinglisted 1952-06-23dividend yield 4.33%

Next earnings ~May 5, 2026 · Ex-dividend Apr 2, 2026 · Dividend $0.63 quarterly

About Bristol-Myers Squibb

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Latest News

BMY catalysts

We track BMY on Sector Watch from primary sources. See its FDA dates, trials and filings

Related Stocksin Pharmaceuticals

Related research

More in Market history

Ready to see the live AI view on BMY?

Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing BMY side-by-side with live signals.